Statin use and cerebral microbleeds in patients with spontaneous intracerebral hemorrhage
10.7619/jcmp.201807005
- VernacularTitle:自发性脑出血患者的他汀应用和脑微出血情况分析
- Author:
Na WANG
1
;
Xuezhang QI
;
Zhigang SHU
;
Bingyin MEI
Author Information
1. 湖北省鄂州市中心医院神经内科
- Keywords:
intracerebral hemorrhage;
microbleeding;
statin
- From:
Journal of Clinical Medicine in Practice
2018;22(7):19-22
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the association between with increased risk of intracerebral hemorrhage (ICH),particularly in elderly patients with previous ICH.So we investigated whether statin use is associated with increased prevalence of microbleeding (MB),particularly cortico-subcortical microbleeding (csMB).Methods The data of 163 cerebral hemorrhage patients with MRI examination within 30 d of onset.The patients were divided into cortical,subcortical microbleeding (csMB) and microbleeding (oMB) locations,and the location and number of microbleed were compared,and patients were divided into groups according to whether statins were used,whether there was microbleeds (MB),cortical or subcortical microbleeding (csMB).Results There were 64％ patients with lobar ICH,53％ with microbleed and 39％ with csMB.The application of statin had lower cholesterol and low-density lipoprotein levels,and patients with statin had higher incidence rate of hypertension,diabetes,dyslipidemia,and antiplatelet disease.The number of oMB in patients with statin and without statin were similar,and statin-treated patients had more csMB (57％ vs.33％,P =0.007),with almost twice of patients without statin treatment (4.6 +2.7 vs.2.4 + 1.8;P ＜ 0.001).Multivariate factor analysis showed that age and statin use were independently risk factorsforMB(OR=l.03;95％ CI:1.00～1.05;P=0.01,0R=2.72;95％ CI:1.02～7.22;P =0.04,respectively) and csMB (OR =1.03;95％ CI:1.00 ～ 1.06;P =0.01 and OR =4.15;95％ CI:1.54 ～ 11.20,P ＜0.01).Conclusion Statin use in patients with ICH is independently associated with MB,especially csMB.Future studies are needed to confirm our findings and to investigate whether csMB can serve as a marker for ICH risk in statin-treated patients.
